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Renoprotective effects of angiotensin II receptor blockade in Diabetic nephropathy is a serious long-term complica-
type 1 diabetic patients with diabetic nephropathy. tion in type 1 diabetes mellitus. Diabetic nephropathy,
Background. Angiotensin I-converting enzyme (ACE) in- characterized by persistent albuminuria, a relentless de-
hibitors reduce angiotensin II formation and induce bradykinin
cline in glomerular filtration rate (GFR), and raised arte-accumulation. Animal studies suggest that bradykinin may play
rial blood pressure, develops in 30 to 40% of all type 1a role for the effects of ACE inhibition on blood pressure
diabetic patients [1]. Previous studies have documentedand kidney function. Therefore, we compared the renal and
hemodynamic effects of specific intervention in the renin- that inhibition of the renin-angiotensin system by angio-
angiotensin system by blockade of the angiotensin II subtype-1 tensin I-converting enzyme (ACE) inhibitors consis-
receptor to the effect of ACE inhibition. tently reduces albuminuria and retards renal injury [2, 3].Methods. A randomized, double-blind, cross-over trial was
However, the principal mechanism of action of theseperformed in 16 type 1 diabetic patients (10 men), age 42 6
renal effects is not completely understood. ACE is not2 years (mean 6 sem). The study consisted of five periods,
each lasting two months. The patients received losartan 50 mg, a very specific enzyme and has other substrates such as
losartan 100 mg, enalapril 10 mg, enalapril 20 mg, and placebo bradykinin. Therefore, ACE inhibitors not only decrease
in random order. At the end of each period, albuminuria, 24- the production of angiotensin II, but also cause accumu-
hour blood pressure, and glomerular filtration rate (GFR) were lation of bradykinin. Bradykinin is a potent vasodilatordetermined.
acting through the release of prostacyclin, nitric oxide,Results. Both doses of losartan and enalapril reduced albu-
and endothelial-derived factors [4]. Recent animal andminuria (P , 0.05) and mean arterial blood pressure (MABP;
P , 0.05), whereas GFR remained stable. Albuminuria was human studies have suggested that bradykinin may play
reduced by 33% (95% CI, 12 to 51) on losartan 50 mg, 44% a role in the effects of ACE inhibition on blood pressure
(95% CI, 26 to 57) on losartan 100 mg, 45% (95% CI, 23 to 61) and kidney function [5, 6]. Furthermore, angiotensin II
on enalapril 10 mg, and 59% (95% CI, 39 to 72) on enalapril
is not only generated by the ACE pathway, but also20 mg, and MABP fell by 9 6 2, 8 6 2, 6 6 3, and 11 6 3
through alternative pathways such as the chymase path-mm Hg (mean 6 sem), respectively. No significant differences
way [7]. These alternative pathways are not affected bywere found between the effects of losartan 100 mg and enalapril
20 mg. HbA1C and sodium intake remained unchanged through- ACE inhibition. Therefore, ACE inhibitors will not com-
out the study, whereas a significant rise in serum potassium pletely block the formation of angiotensin II. Specific
occurred during ACE inhibition. intervention in the renin-angiotensin system by angio-
Conclusion. The angiotensin II subtype 1 receptor antago-
tensin II receptor blockade has no effect on bradykininnist, losartan, reduces albuminuria and MABP similar to the
metabolism, but antagonizes angiotensin II generated byeffect of ACE inhibition. These results indicate that the reduc-
tion in albuminuria and blood pressure during ACE inhibition any pathway. This may result in a more effective block-
is primarily caused by interference in the renin-angiotensin ade of the renin-angiotensin system, but eliminates the
system. Our study suggest that losartan represents a valuable possibility of a positive contribution to the renal and
new drug in the treatment of hypertension and proteinuria in hemodynamic effects from bradykinin accumulation. Ittype 1 diabetic patients with diabetic nephropathy.
has previously been shown that the angiotensin II recep-
tor antagonist losartan induces changes in blood pressure
and proteinuria similar to the changes induced by ACEKey words: IDDM, proteinuria, hypertension, glomerular filtration
rate, losartan, renin-angiotensin system. inhibition in nondiabetic kidney disease [8].
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Table 1. Clinical and laboratory data in 16 Type 1 diabetic patientsbetic nephropathy, and to compare the renal and hemo-
with diabetic nephropathy
dynamic effects with the effects of ACE inhibition.
Sex males/females 10/6
Age years 4262
Diabetes duration years 3362METHODS
Albuminuria mg · 24 h21a 1156 (643–2080)
Subjects and design Systolic blood pressure (24 h) mm Hg 14763
Diastolic blood pressure (24 h) mm Hg 8262Sixteen patients with type 1 diabetes mellitus and per- Mean arterial blood pressure (24 h) mm Hg 10462
sistent albuminuria (.300 mg/24 hours) attending the Glomerular filtration rate ml · min21 · 1.73 m22 9066
Steno Diabetes Center were included in the study. Dia- Data are mean 6 SEM.
a Geometric mean (95% CI)betic nephropathy was diagnosed clinically in patients
with persistent albuminuria (.300 mg/24 h), diabetic
retinopathy, a diabetes duration of more than 10 years,
and the absence of any clinical or laboratory evidence
immediately before the day of the visit. In addition, uri-
of other kidney or renal tract disease [9]. All patients
nary excretion of sodium and urea (Cobas Mira Plus;
fulfilled the following inclusion criteria: diabetic ne-
Roche, Montclair, NJ, USA) was measured from thephropathy, GFR .60 mL/min/1.73 m2, office blood pres-
three urine collections. The urea excretion was used tosure .145/85 mm Hg, and age between 18 and 70 years.
calculate the protein intake from the nitrogen contentPatients were excluded if they had a history of malignant
of the urea and an estimated value of nonurea nitrogenhypertension, congestive heart failure, myocardial in-
of 31 mg/kg · day21 [15].farction, or stroke within the last three months. None of
From venous blood samples, serum potassium, so-the patients had their intake of protein or salt restricted.
dium, creatinine, and cholesterol concentrations wereDrug compliance was assessed by tablet counts. Patients
determined (Cobas Mira Plus; Roche), and hemoglobinwho forgot to take the study medication more than once
A1C (HbA1c) was measured by high-performance liquida week were to be excluded from the study. On the days
chromatography (normal range 4.1 to 6.4%; Variant;of kidney function studies, patients had their normal
Bio-Rad Laboratories, Hercules, CA, USA). Blood sam-breakfast and morning dose of insulin, but did not take
ples for the determination of angiotensin II levels werethe study medication. The study was approved by the
drawn in prechilled tubes after 30 minutes of supinelocal ethical committee, and the investigated patients all
rest and were immediately centrifuged at 48C. Plasmagave their informed consent.
concentrations were measured radioimmunologically ac-Our study was designed as a randomized, double-
cording to the method of Kappelgaard, Nielsen, andblind, cross-over trial. Each treatment period consisted
Giese [16].of two months in which the patients received losartan
Blood pressure values are based on 24-hour ambula-50 mg, losartan 100 mg, enalapril 10 mg, enalapril 20
tory blood pressure measurements performed with themg, and placebo in random order. Before enrollment,
Takeda TM2420 (A&D, Tokyo, Japan) device. Bloodall antihypertensive medication, including diuretics, were
pressures were measured every 15 minutes during thewithdrawn for at least four weeks. At the end of each
day (7:00 a.m. to 11:00 p.m.) and every 30 minutes duringtwo-month treatment period, GFR, 24-hour blood pres-
the night (11:00 p.m. to 7:00 a.m.). Values were averagedsure, and proteinuria were determined.
for each hour before calculating the 24-hour blood pres-
sure.Laboratory procedures
Glomerular filtration rate was measured at 8:00 a.m.
Data analysisafter a single intravenous injection of 3.7 MBq 51Cr-
Data are expressed as mean 6 sem, except for theethylenediaminetetraacetic acid (EDTA) by determin-
excretion of albumin, IgG, and retinol-binding protein,ing the radioactivity in venous blood samples taken 180,
which were logarithmically transformed before analysis200, 220, and 240 minutes after the injection [10, 11].
because of their skewed distribution and are given asThe results were standardized for 1.73 m2 body surface
the geometric means (95% CI). Data are analyzed byarea, using the patients surface area at the start of the
analysis of variance according to a general linear model,study. The mean coefficient of variation in GFR of each
repeated-measures method. Results from the end of thepatient from day to day was 4%.
treatment periods are compared with the end of theAlbuminuria and urinary retinol-binding protein was
placebo period. Subsequently, the effects of losartan 100determined by enzyme-linked immunosorbent assay
mg were compared with the effects of enalapril 20 mg.(ELISA) [12, 13], as the geometric mean of three consec-
A P value , 0.05 was considered significant (two tailed).utive 24-hour urine collections, completed immediately
Data were evaluated using SPSS 7.5 (SPSS Inc., Chicago,before each visit. Urinary IgG excretion was determined
by ELISA [14] from one 24-hour urine sample collected IL, USA).
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Table 2. Systemic blood pressure and kidney function in 16 Type 1 diabetic patients with diabetic nephropathy during
treatment with losartan, enalapril, and placebo
Losartan Enalapril
Placebo 50 mg 100 mg 10 mg 20 mg
MABPa (24 h) mm Hg 10462 9562c 9662c 9863c 9363c
Systolic BPa (24 h) mm Hg 14763 13764c 13563c 14164c 13564c
Diastolic BPa (24 h) mm Hg 8262 7561c 7662c 7762c 7362c
GFRa ml/min/1.73 m2 9066 9166 89 66 89 66 8766
Urinary albuminb mg/24 h 1156 (643–2080) 775 (445–1349)c 651 (377–1126)c 631 (340–1173)c 477 (251–910)c
Urinary IgGb mg/24 h 88 (47–164) 55 (36–72)c 43 (26–73)c 46 (26–82)c 31 (18–56)c
Urinary retinol binding proteinb lg/24 h 383 (171–860) 323 (180–581) 306 (151–620) 264 (106–656) 312 (150–648)
a Mean 6 SEM
b Geometric mean (95% confidence interval)
c P , 0.05 vs. placebo
Table 3. Laboratory data in 16 Type 1 diabetic patients with diabetic nephropathy during treatment with losartan, enalapril and placebo
Losartan Enalapril
Placebo 50 mg 100 mg 10 mg 20 mg
Serum potassium mmol/L 4.0060.1 4.1860.1 4.1360.1 4.3160.1a 4.2960.1a
Serum sodium mmol/L 14060.5 13960.7 13960.6 13960.5 13960.4
Serum creatinine lmol/L 9665 9465 9267 9665 8966
Serum angiotensin II pmol/L 11.061.8 24.365.0a 37.6610.8a 8.061.3a 7.861.0a
Serum cholesterol mmol/L 5.460.3 5.260.3 5.160.3 5.160.2 5.160.2
HbA1C % 8.860.3 9.060.4 9.260.3 8.860.4 8.960.3
Urinary sodium mmol/24 h 151617.6 168614.8 165620.3 155619.8 157616.1
Dietary protein intake g/day/kg body wt 1.0160.07 1.1860.12 1.0160.08 1.0160.08 1.0060.08
Data are mean 6 SEM.
a P , 0.05 vs. placebo
RESULTS excretion decreased 38% (1 to 61) and 51% (31 to 64)
on the two doses of losartan, and 48% (18 to 66) andAll 16 included patients completed the study (Table 1).
65% (49 to 75) during treatment with enalapril 10 andFive patients received furosemide during all treatment
20 mg, respectively (P , 0.05). We found no significantperiods to prevent peripheral edema, but no other con-
correlations between changes in blood pressure in eachcomitant medications were given. No patients reported
side-effects that could be related to the study medication. individual and changes in albuminuria or urinary IgG
In the statistical analysis of the data, we found no evi- excretion. Urinary levels of retinol binding protein were
dence of carryover or sequence effects in the treatment unchanged during all treatment periods. No significant
periods. differences were found between the effects of losartan
Arterial blood pressure, albuminuria, and urinary ex- 100 mg and enalapril 20 mg on any of the previously
cretion of IgG decreased significantly from placebo val- mentioned parameters (Fig. 1).
ues on both doses of losartan and enalapril (Table 2). The GFR remained stable during all treatment peri-
The 24-hour mean arterial blood pressure decreased ods. Urinary sodium excretions were marginally elevated
from 104 6 2 mm Hg (mean 6 SEM) in the placebo above upper normal level (150 mmol/24 h) during all
period to 95 6 2 mm Hg during treatment with losartan
five treatment periods, but no significant differences50 mg, 96 6 2 mm Hg during losartan 100 mg, 98 6 3
were found between the five periods. Cholesterol, creati-mm Hg during enalapril 10 mg, and 93 6 3 mm Hg
nine, and sodium in serum remained unchanged, whereasduring treatment with enalapril 20 mg (P , 0.05). The
serum potassium increased significantly from placebo24-hour systolic and diastolic blood pressures were all
values during both enalapril treatment periods (P ,significantly reduced on both doses of losartan and enala-
0.05). No changes from placebo values were found inpril (P , 0.05; Table 2). Albuminuria was reduced from
the losartan treatment periods. As expected, angiotensinplacebo values by 33% (95% CI, 12 to 51) during treat-
II levels in plasma were significantly increased duringment with losartan 50 mg, 44% (26 to 57) on losartan
both doses of losartan and were decreased during enala-100 mg, 45% (23 to 61) on enalapril 10 mg, and 59%
(39 to 72) on enalapril 20 mg (P , 0.05). Urinary IgG pril treatment (Table 3).
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reduction in the study of Gansevoort et al was higher
during treatment with both losartan and enalapril com-
pared with our study. This difference is probably ex-
plained by the different methods used for blood pressure
measurements in the two studies. Blood pressure values
in our study are based on 24-hour measurements,
whereas peak value office recordings are used in the
study of Gansevoort et al [8].
Numerous studies in diabetic and nondiabetic ne-
phropathies have documented that proteinuria is an im-
portant progression promoter, that is, a risk factor for
loosing filtration power, as reviewed by Remuzzi and
Fig. 1. Relative changes in glomerular filtration rate (j), mean arterial Bertani [18] and Rossing [19]. Furthermore, studies ofblood pressure (r), and albuminuria (d) compared with placebo in 16
diabetic [20, 22] and nondiabetic [23, 24] renal diseasetype I diabetic patients with diabetic nephropathy. *P , 0.05.
have indicated that an initial reduction in proteinuria
after the onset of antihypertensive medication, with and
without ACE inhibition (surrogate endpoint), predicts
DISCUSSION the long-term preservation of kidney function (primary
Our study demonstrates that losartan reduces blood endpoint). Consequently, these data suggest that angio-
pressure and proteinuria similar to the effect of an ACE tensin II receptor blockade may have a long-term reno-
inhibitor in hypertensive type 1 diabetic patients with protective effect.
diabetic nephropathy. Our study is the first, to our knowl- Animal and human studies have suggested that brady-
edge, to investigate the effects of an angiotensin II sub- kinin may play a role in the effects of ACE inhibition
type 1 receptor antagonist in hypertensive type 1 diabetic on blood pressure and kidney function, such as lowering
patients with diabetic nephropathy. The results suggest albuminuria. ACE inhibitors inactivate kininase II, a
that the reduction in proteinuria and blood pressure is kinin-degrading enzyme, and thereby cause accumula-
primarily caused by interference in the renin-angiotensin tion of bradykinin. The contribution of bradykinin to
system. the effect of ACE inhibition has recently been investi-
We found a larger relative decline (insignificant) in gated in a human study by Gainer et al [6]. The co-
urinary IgG excretion as compared with the reduction administration of a bradykinin antagonist and an ACE
in albuminuria during treatment with the high doses of inhibitor significantly reduced the short-term hypoten-
the drugs, suggesting an improvement in the size-selec- sive response as compared with the ACE inhibitor alone
tive properties of the glomerular capillary membrane. in normotensive and mild hypertensive salt-depleted
Retinol-binding protein, measured for evaluation of tu- subjects [6].
bular function, remained unchanged from placebo dur- Another subject in the discussion of angiotensin II
ing all treatment periods, indicating that the reduction receptor antagonism and ACE inhibition is the genera-
in proteinuria is mediated by changes in glomerular func- tion of angiotensin II through non-ACE pathways. Stud-
tion and not through modifications in tubular reabsorp- ies by Hollenberg, Fisher, and Price have suggested that
tion. one third of the angiotensin II formation in healthy,
Even though our study did not reveal a significant salt-depleted humans occurs by a non-ACE dependent
correlation between the reduction of arterial blood pres- pathway, probably by the chymase pathway [7]. More-
sure and the decrease in proteinuria, several previous over, it is suggested that these non-ACE pathways may
studies dealing with blood pressure-lowering drugs not be quantitatively even more important in diabetes [7].
interfering with the renin-angiotensin system have clearly Whether a combined therapy of ACE inhibitors and
documented a significant blood pressure impact on pro- angiotensin II receptor antagonists, in order to benefit
teinuria, as reviewed by Parving [17]. This beneficial both from the bradykinin effect and a more specific an-
effect is probably due to a reduction in glomerular capil- giotensin II blockade, would increase the renoprotective
lary hydraulic pressure. effect remains to be elucidated.
Our results are in complete agreement with the find- Studies in streptozotocin diabetic rats have demon-
ings of Gansevoort, De Zeeuw, and De Jong [8], who strated that both angiotensin II receptor antagonists and
investigated the effects of losartan 50 and 100 mg and ACE inhibitors blocked the development of hyperten-
enalapril 10 and 20 mg in patients with nondiabetic kid- sion, significantly decreased albuminuria, and protected
ney disease. Albuminuria is equally reduced, and kidney against focal glomerular sclerosis [25, 26]. Similar results
function remains stable during all treatment periods in were found in streptozotocin diabetic mice with diabetic
glomerulopathy [27]. Size-selective properties of the glo-both studies. However, the magnitude of blood pressure
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merular membrane in experimental diabetic rats have sure are reduced by the angiotensin II receptor antago-
been investigated during treatment with enalapril and nist, losartan, similar to the effect of ACE inhibition.
losartan in two studies of Remuzzi et al [28, 29]. Enalapril These data support the hypothesis that the renoprotec-
significantly reduced the fractional clearances of neutral tive effects of ACE inhibition are primarily mediated by
dextran molecules larger than 52 A˚ compared with pla- interference in the renin-angiotensin system. Our study
cebo-treated animals. The effect of losartan on glomeru- suggests that losartan represents a valuable new drug in
lar permselective function in diabetic rats was evaluated the treatment of hypertension and proteinuria in type 1
with Ficoll, polydisperse neutral macromolecules of diabetic patients with diabetic nephropathy.
graded size, as a tracer. Losartan lowered the fractional
clearance of the tracer for all molecular radii, suggesting ACKNOWLEDGMENTS
that the effect of both enalapril and losartan on glomeru- The study was supported by a medical school grant from Merck,
lar size-selective functions can be attributed to the func- Sharp & Dohme. We acknowledge the assistance of Ms. Berit R.
Jensen, Ms. Ulla Smidt, Ms. Inge-Lise Rossing, and Ms. Marja Deckert.tion of angiotensin II.
The study was presented at the 35th Annual Meeting of the EASD,The contribution of bradykinin to the effect of ACE
September 1999.
inhibition has also been investigated in animal studies.
Reprint requests to Dr. Steen Andersen, Steno Diabetes Center, NielsThe increase in glomerular blood flow induced by ACE
Steensensvej 2, 2820 Gentofte, Copenhagen, Denmark.inhibition in rats is reported to be mainly caused by
E-mail: STAN@dadlnet.dk
dilation of the efferent arteriole. This effect can be atten-
uated by a specific bradykinin antagonist [30]. In con-
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